These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7631299)

  • 1. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene.
    Bokarewa MI; Bremme K; Falk G; Sten-Linder M; Egberg N; Blombäck M
    Thromb Res; 1995 May; 78(3):193-200. PubMed ID: 7631299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies.
    Galli M; Finazzi G; Bevers EM; Barbui T
    Blood; 1995 Jul; 86(2):617-23. PubMed ID: 7605991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of phospholipid antibodies in selected thrombophilic women differing in genotype at the 506 site of factor V.
    Bokarewa MI; Bremme K
    Eur J Haematol; 1998 Jul; 61(1):21-6. PubMed ID: 9688288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
    Hoagland LE; Triplett DA; Peng F; Barna L
    Thromb Res; 1996 Sep; 83(5):363-73. PubMed ID: 8873345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiphospholipid antibodies in children without and in adults with and without thrombophilia.
    Siemens HJ; Gutsche S; Brückner S; Bucsky P; Katus HA
    Thromb Res; 2000 May; 98(4):241-7. PubMed ID: 10822070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated protein C resistance phenotype in patients with antiphospholipid antibodies.
    Aznar J; Villa P; España F; Estellés A; Grancha S; Falcó C
    J Lab Clin Med; 1997 Aug; 130(2):202-8. PubMed ID: 9280148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipid antibodies and resistance to activated protein C in women with thrombophilia.
    Bokarewa MI; Blombäck M; Bremme K
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):417-22. PubMed ID: 8589207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
    Ames PR; Pyke S; Iannaccone L; Brancaccio V
    Thromb Haemost; 1995 May; 73(5):768-73. PubMed ID: 7482401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis.
    Bokarewa MI; Blombäck M
    Semin Hematol; 1997 Jul; 34(3):235-43. PubMed ID: 9241708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated protein C resistance: molecular mechanisms.
    Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
    Moore GW; Rangarajan S; Savidge GF
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay.
    Gardiner C; Cohen H; Jenkins A; Machin SJ; Mackie IJ
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):477-83. PubMed ID: 16905952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new variant of interaction between phospholipid antibodies and the protein C system.
    Bokarewa MI; Blombäck M; Egberg N; Rosén S
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):37-41. PubMed ID: 8180337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity.
    Rolla R; Vidali M; Serino R; Pergolini P; Albano E; Bellomo G
    Clin Exp Immunol; 2007 Jul; 149(1):63-9. PubMed ID: 17488295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C.
    Galli M; Ruggeri L; Barbui T
    Blood; 1998 Mar; 91(6):1999-2004. PubMed ID: 9490682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay.
    Kalafatis M; Haley PE; Lu D; Bertina RM; Long GL; Mann KG
    Blood; 1996 Jun; 87(11):4695-707. PubMed ID: 8639839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.